New-Age Vaccine Adjuvants: Friend or Foe? - A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity - BioPharm


New-Age Vaccine Adjuvants: Friend or Foe?
A major unsolved challenge in adjuvant development is how to achieve a potent adjuvant effect while avoiding reactogenicity or toxicity

BioPharm International

92. Kramp WJ, Six HR, Kasel JA. Postimmunization clearance of liposome entrapped adenovirus type 5 hexon. Proc Soc Exp Biol Med 1982;169:135–139.

93. Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Gluck R, Herzog C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997;15:1209–1213.

94. Powers DC, Manning MC, Hanscome PJ, Pietrobon PJ. Cytotoxic T lymphocyte responses to a liposome-adjuvanted influenza A virus vaccine in the elderly. J Infect Dis 1995;172:1103–1107.

95. Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol 2003;69:560–567.

96. Owais M, Gupta CM. Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur J Biochem 2000;267:3946–3956.

97. Zheng L, Huang XL, Fan Z, Borowski L, Wilson CC, Rinaldo, Jr. CR. Delivery of liposome-encapsulated HIV type 1 proteins to human dendritic cells for stimulation of HIV type 1-specific memory cytotoxic T lymphocyte responses. AIDS Res Hum Retroviruses 1999;15:1011–1020.

98. Guy B, Pascal N, Francon A, Bonnin A, Gimenez S, Lafay-Vialon E, Trannoy E, Haensler J. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 2001;19:1794–1805.

99. Zayas C, Bracho G, Lastre M, Gonzalez D, Gil D, Acevedo R, del Campo J, Taboada C, et al. Scale up of proteoliposome derived Cochleate production. Vaccine 2006;24 Suppl 2:S2–94–95.

100. Cooper PD. Vaccine adjuvants based on gamma inulin. In Vaccine design: the subunit and adjuvant approach. Powell MF (ed.), Plenum Press, New York 1995;559–580.

101. Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 2006;24 Suppl 2:S2–26–29.

102. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004;82:488–496.

103. Silva DG, Cooper PD, Petrovsky N. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol Cell Biol 2004;82:611–616.

104. Kornbluth RS, Stone GW. Immunostimulatory combinations: designing the next generation of vaccine adjuvants. J Leukoc Biol 2006;80:1084–1102.

105. Rezaei N. Therapeutic targeting of pattern-recognition receptors. Int Immunopharmacol 2006;6:863–869.

106. Su,B, Silver PB, Grajewski RS, Agarwal RK, Tang J, Chan CC, Caspi RR. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol 2005;175:6303–6310.

107. van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol 2006;27:49–55.

108. O'Hagan DT, Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 2004;21:1519–1530.

109. Singh M, and O'Hagan DT. Recent advances in vaccine adjuvants. Pharm Res 2002;19:715–728.

110. Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 2006;24:1680–1686.

111. Cooper PD, McComb C, Steele EJ. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 1991;9:408–415.

blog comments powered by Disqus



Merck KGaA Announces Acquisition of Sigma-Aldrich for $17 Billion
September 22, 2014
Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Author Guidelines
Source: BioPharm International,
Click here